Loading...

ANTX AN2 THERAPEUTICS INC US FDA Inspections 8-K Filing

N2 T

NTX

AN2 THERAPEUTICS INC

(ANTX)

2023 8-K

Show Summary

Summary

Equity Offerings

Investor Meetings

Earnings Releases

Financial Results

Q3 Financial Results

Rights Agreement

Q2 Financial Results

Workforce Reduction and Stu...

Financial Results Announcement

Earnings Reports

Clinical Trial Pause

Earnings Reports

Other Special Situation

Appointment and Departure o...

Investment Offering

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

External Links:

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease.

AI Assistant

AN2 THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.